Amgen Inc. $AMGN Position Increased by WBI Investments LLC

WBI Investments LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 193.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 2,628 shares of the medical research company’s stock after buying an additional 1,731 shares during the quarter. WBI Investments LLC’s holdings in Amgen were worth $742,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Evelyn Partners Investment Management LLP acquired a new position in Amgen in the second quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in Amgen during the 2nd quarter valued at approximately $32,000. Cloud Capital Management LLC bought a new position in Amgen during the 3rd quarter worth $34,000. AXS Investments LLC bought a new stake in Amgen in the third quarter valued at $42,000. Finally, Winnow Wealth LLC bought a new position in shares of Amgen during the third quarter worth about $47,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Leerink Partners reissued a “market perform” rating and set a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Barclays started coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Daiwa Securities Group increased their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Finally, Argus lifted their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $354.00.

Amgen Trading Down 2.7%

Shares of NASDAQ:AMGN opened at $351.48 on Thursday. The company has a 50 day moving average of $359.46 and a 200-day moving average of $326.94. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a market cap of $189.47 billion, a P/E ratio of 24.70, a P/E/G ratio of 3.58 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the business earned $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.